Michael Crowley, Head Of Business Development Roche .

1y ago
14 Views
2 Downloads
2.17 MB
16 Pages
Last View : 2m ago
Last Download : 7m ago
Upload by : Duke Fulford
Transcription

Roche Company PresentationMichael Crowley, Head of Business Development RocheResearch & Early Development, Pharma Partnering

The Roche Group: aninnovation-driven companyWhy we make agood partnerWhat we are lookingfor from you2

The Roche Group: aninnovation-driven companyWhy we make agood partnerWhat we are lookingfor from you3

The Roche GroupA leading healthcare company dedicated to innovation in a sustainable way189661.5 bnFounded in BaselFamily still holdsmajority stakeBiotechSales 2019 (CHF) 197’735R&D investor inhealthcareEmployees worldwideLasting 30 medicineson World HealthOrganization List ofEssential Medicines1 GenentechGenentech1, firstpublicly-ownedbecame a full member of the Roche group in March 200963,000,000people treatedworldwide with ourmedicines in 2019 and Sustainable36Among top companies in Dow JonesSustainability Index (Life Sciences Sector)for 10 consecutive yearsFDA BreakthroughDesignations4

The leader in personalized healthcareOptimally positioning us for the futureCombiningpharmaceuticals anddiagnostics under one rooftogether with deep know-howin molecular biology and datascience, make Roche aunique partner to drive nextstep in the evolutionof healthcare.Leader in PharmaLeader in DiagnosticsDiagnosisDecision SupportTherapyTherapy monitoring5

Our unique innovation modelProviding scientific freedom to work, think and address problemsin different waysResearch and Early DevelopmentLate Stage and Commercial (Pharma)gREDGlobal lizationIndependent Centers forResearch and Early DevelopmentRoche Pharma PartneringManaging over 220 partnershipsWorldwide execution6

The Roche Group: aninnovation-driven companyWhy we make agood partnerWhat we are lookingfor from you7

Global presencePharma Partnering officesCambridgeSouth San FranciscoBostonBaselTokyoShanghaiWith around 120 people worldwide, Pharma Partneringoffers speed, flexibility and accessibility to partners.8

Our approach to Partnering in the Pharma industryWe value external innovation and bring our experts to the table9

Because a great idea is a great idea no matter where it comes from 50%of R&D pipelineinvolve a partnership 40%of total Pharma salesgenerated from partneredor in-licensed products10

Roche launched 20 new molecules since 201115 out of the 20 are partnered medicines2011Partnered medicines20122013201420152016201720182019202011

We value external innovationComplementing our internal innovation and expertise211AcquisitionsProductout-licensing agreementsand divestments16Agreements derived fromexisting alliances14Product, technologyor discovery licenseagreements7819new agreementsin 2019PHC agreementsAgreements entered in:››››OncologyImmunologyOphthalmologyGene therapy››››NeurologyTechnology PlatformsPHCRare Diseases16Research and technologyand clinical trial collaborations12

The Roche Group: aninnovation-driven companyWhy we make agood partnerWhat we are lookingfor from you13

Our focus areasSeeking great science across multiple therapeutic areasDigital &Personalized Healthcare Robust data sets Advanced Analytics (artificialintelligence incl. machinelearning and deep-learningmodels)Immunology Gastroenterology, Respiratory,Rheumatology Innate, Adaptive, Fibrosis,Tolerance and TissueRegeneration TargetsInfectiousDiseasesNeuroscience Hepatitis B Neurodegeneration (e.g. AD,Parkinson's disease, HD, ALS) Respiratory Viruses Neuroinflammation (e.g. MS) Multidrug-resistant, Gramnegative Bacterial Infections Neurodevelopmental (e.g. ASD) Pain (non-opioid treatments forchronic pain) Digital and mobile technologiesOncology & CancerImmunotherapy Oncogenic drivers Synthetic lethality Adaptive and innate immunity NeoantigensOphthalmology Retinal diseases and longacting ocular drug deliverysolutions Glaucoma and dry eye diseaseRare Diseases Monogenetic rare diseasesResearchTechnologies Novel modalities & enablingtechnologies to expanddruggable target space Targeted, intracellular delivery Stromal biology Artificial intelligence for drugdiscovery Cell therapies Genomic Medicine platforms14

15

Doing now what patients need next16

Michael Crowley, Head of Business Development Roche Research & Early Development, Pharma Partnering Roche Company Presentation. 2 The Roche Group: an innovation-driven company Why we make a good partner What we are looking for from you. 3 What we are looking The Roche Group: an for from you